FindTrial
Sign In

Handling Medium for ICSI With Ionomycin and Latrunculin A

Latrunculin A and Ionomycin as a Handling Medium for ICSI

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03678610
Enrollment
700
Registered
2018-09-19
Start date
2018-09-25
Completion date
2019-05-01
Last updated
2019-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Using Latrunculin A and Ionomycin would improve the outcome of ICSI if the handling medium during the ICSI procedure has them.

Interventions

OTHERDoing ICSI I a medium supplemented with Ionomycin and Latrunculin A

Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes

Sponsors

Banoon IVF Center
CollaboratorOTHER
Qena Fertility Center
CollaboratorUNKNOWN
Ibn Sina Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

* indication for ICSI

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Fertilization rate6 days of culture

Secondary

MeasureTime frameDescription
Rates of Blastocyst formation and quality6 days of cultureNumber of formed blastocysts and blastocysts with good-quality per fertilized oocytes
embryo utilization rate6 days of culture—
clinical pregnancy ratethree months—
ongoing pregnancy rate12 weeks—

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026